Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Rhea-AI Summary

Eloxx Pharmaceuticals (Nasdaq:ELOX) priced a public offering totaling approximately $66.0 million, consisting of 2,975,000 common shares at $11.00 and pre-funded warrants for up to 3,025,000 shares at $10.99. The common stock is expected to begin trading on the Nasdaq Capital Market on June 9, 2026, with closing targeted for June 10, 2026, subject to customary conditions.

Positive

• Gross proceeds of approximately $66.0 million expected from offering
• Uplisting to Nasdaq Capital Market with trading expected June 9, 2026
• Flexibility via mix of common stock and 3,025,000 pre-funded warrants

Negative

• Equity financing likely to dilute existing common shareholders
• Offering proceeds $66.0 million stated before underwriting fees and expenses

News Market Reaction – ELOX

+170.52% 75.2x vol

12 alerts

+170.52% Session close to close

+42.0% Peak in 4 hr 25 min

$7.76M Market Cap

75.2x Rel. Volume

In the Jun 9 session, ELOX gained 170.52%, reflecting a significant positive market reaction. Argus tracked a peak move of +42.0% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 75.2x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +170.5% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +170.5% in the session following this news. A strong positive reaction aligns with the capital-raising and uplisting milestone, as Eloxx secured a $66.0 million public offering and transition to the Nasdaq Capital Market. Prior S-1/A filings highlighted limited cash and going concern language, so improved capitalization could have supported bullish interpretation. Investors would still have needed to weigh dilution impact and prior reverse split dynamics when assessing durability of gains.

Key Figures

Gross proceeds: $66.0 million Common shares offered: 2,975,000 shares Common share price: $11.00 per share +5 more

8 metrics

Gross proceeds $66.0 million Public offering of common stock and pre-funded warrants

Common shares offered 2,975,000 shares Public offering common stock tranche

Common share price $11.00 per share Public offering price for common stock

Pre-funded warrants 3,025,000 warrants Pre-funded warrants offered in lieu of common shares

Pre-funded warrant price $10.99 per warrant Public offering price for pre-funded warrants

Warrant exercise price $0.01 per share Exercise price for each pre-funded warrant share

Nasdaq listing date June 9, 2026 Expected start of trading on Nasdaq Capital Market under ELOX

Offering closing date June 10, 2026 Expected closing of the public offering

Key Terms

pre-funded warrants, nasdaq capital market, form s-1, registration statement, +1 more

5 terms

pre-funded warrants financial

"pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

nasdaq capital market regulatory

"shares of common stock are expected to begin trading on the Nasdaq Capital Market on June"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

form s-1 regulatory

"A registration statement on Form S-1 (File No. 333-295651) relating to the offering"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

registration statement regulatory

"A registration statement on Form S-1 (File No. 333-295651) relating to the offering"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus regulatory

"The proposed offering is being made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of $66.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Eloxx. The shares of common stock are expected to begin trading on the Nasdaq Capital Market on June 9, 2026, under the symbol "ELOX". The offering is expected to close on June 10, 2026, subject to the satisfaction of customary closing conditions.

Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.

A registration statement on Form S-1 (File No. 333-295651) relating to the offering has been filed with the Securities and Exchange Commission (the "SEC") and became effective on June 8, 2026. The proposed offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including without limitation, statements regarding the anticipated proceeds from the offering, the expected trading date for the shares of common stock on the Nasdaq Capital Market and the anticipated timing of closing of the offering are forward-looking statements. Forward-looking statements can be identified by the words "aim," "may," "will," "would," "should," "expect," "explore," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "seeks," or "continue" or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to the Company. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to market conditions and other important factors discussed under the caption "Risk Factors" in the Company's Registration Statement on Form S-1 filed on June 4, 2026.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Eloxx Pharmaceuticals Investor Relations
ir@eloxxpharma.com
(781) 577-5300

View original content to download multimedia:https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-inc-announces-pricing-of-66-0-million-public-offering-and-uplisting-to-nasdaq-302794598.html

SOURCE Eloxx Pharmaceuticals, Inc.

FAQ

What did Eloxx (Nasdaq:ELOX) announce about its June 2026 public offering?

Eloxx announced a public offering expected to raise about $66.0 million in gross proceeds. According to Eloxx, the deal includes common shares and pre-funded warrants, with all securities sold by the company itself.

How many Eloxx (ELOX) shares and pre-funded warrants are included in the 2026 offering?

The offering includes 2,975,000 common shares and pre-funded warrants for up to 3,025,000 shares. According to Eloxx, this structure provides investors alternatives between immediate equity and low-exercise-price pre-funded warrants.

What is the pricing of Eloxx (ELOX) common stock and pre-funded warrants in the offering?

Common stock is priced at $11.00 per share and pre-funded warrants at $10.99. According to Eloxx, the warrant price equals the share price less the $0.01 per-share exercise price.

When will Eloxx (ELOX) begin trading on the Nasdaq Capital Market after the uplisting?

Eloxx common stock is expected to begin trading on the Nasdaq Capital Market on June 9, 2026. According to Eloxx, the shares will trade under the existing ticker symbol ELOX.

When is the expected closing date for the Eloxx (ELOX) June 2026 public offering?

The offering is expected to close on June 10, 2026, subject to customary conditions. According to Eloxx, completion depends on satisfaction of standard closing requirements for underwritten offerings.

Who are the underwriters for the Eloxx (ELOX) $66.0 million offering?

Leerink Partners and Guggenheim Securities are joint bookrunning managers, with LifeSci Capital as passive bookrunner. According to Eloxx, these firms are managing marketing and distribution of the offered securities.